Sanofi (SNY.US) launches a new antibody drug on the market.

According to the Wisdom Financial APP, on May 8th, the official website of the CDE showed that Sanofi's "injectable Capstasertuzumab monotherapy" has been listed for sale. It is indicated for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy, and is suitable for adults and adolescents aged 12 and above weighing at least 40kg. This indication was previously included in priority review.